302 medical listed companies, 3 with revenue exceeding 3 billion yuan!

[pharmaceutical network industry trends] biomedical enterprises have always been the "sweet cake" of the capital market, with a large number of successful listed enterprises As of September 20, 2019, 302 listed biomedical companies have successively published the 2019 semi annual report An organization selected enterprises with market value of more than 1 billion yuan and medical service revenue accounting for more than 50% of the total operating revenue from A-share and Hong Kong stock, and summarized the operating revenue, net profit and sales expense in the first half of 2019 It is found that compared with the same period last year, the performance of many enterprises has fluctuated significantly From the perspective of business income, the enterprises with more than 3 billion yuan are aer Ophthalmology, meinian health and global medical On the evening of August 22, aer ophthalmology disclosed the 2019 half year report In the first half of the year, the company's net income continued to maintain a steady growth On the basis of the high base of the same period last year, the company achieved an operating income of 4.749 billion yuan, an increase of 25.64% year on year; in the first half of the year, the company's revenue from optometry services increased by more than 30%, with a gross profit margin of 53.06%, accounting for 17.65% of the total revenue; the revenue from refractive surgery, anterior surgery and posterior surgery also maintained a growth rate of about 20% In the same month, meinian health released the semi annual report, which showed that in the first half of this year, the revenue was 3.641 billion yuan, up 2.93% year on year; the net profit attributable to shareholders of listed companies was 17 million yuan, down 89.40% year on year; the net profit attributable to shareholders of listed companies minus non recurring profit and loss was 136 million yuan, down 251.24% year on year For the reason of the decline of net profit in the first half of 2019, meinian Health said that it was only a temporary state On August 27, universal healthcare also announced its results in the first half of 2019 The group's revenue was 3.195 billion yuan, an increase of 52.5% over the same period of last year; its profit during the realization period was 873 million yuan, an increase of 19.0% over the same period of last year; the company's ordinary equity interest holders should account for 812 million yuan, an increase of 10.4% over the same period of last year The net profits of the three enterprises have declined significantly In terms of the net profits, Evergrande health, Hengkang medical and innovative medical have all experienced a significant decline in the first half of this year Evergrande health released its performance in the first half of 2019, and the company achieved an operating revenue of 2.648 billion yuan (RMB, the same below), a year-on-year increase of 132.1%; a gross profit of 611 million yuan, a year-on-year increase of 10.9%; and a temporary loss of 1.984 billion yuan in terms of net profit due to the investment in transformation and vehicle building According to the first half year report of Hengkang medical, the company's half year operating revenue was 1853036019.05 yuan, a year-on-year decrease of 0.48%, and the net profit attributable to shareholders of the listed company was - 61327122.61 yuan, a year-on-year decrease of 184.8% In the first half of the year, innovative medical announced that the company's half year operating revenue was 486430282.69 yuan, a year-on-year decrease of 1.89%, and the net profit attributable to shareholders of the listed company was - 40373368.19 yuan, a year-on-year decrease of 145.66% The proportion of sales expenses of two enterprises is 0 In terms of sales expenses, the proportion of sales expenses of two biomedical enterprises is 0, which are HuaSu holding and national medicine respectively In the first half of the year, HuaSu holdings announced that the company's semi annual operating revenue was 35089240.80 yuan, a year-on-year decrease of 97.01%, and the net profit attributable to shareholders of the listed company was - 8374446.61 yuan However, in the first half of the year, its sales expense was 0, down 100% compared with 708100 yuan in the same period of last year The semi annual report pointed out that it was due to the suspension of bulk trade business In the first half of 2019, international medicine achieved a revenue of 443 million yuan, a decrease of 72.47% over the same period of last year; the net profit attributable to shareholders of listed companies was 5.025 million yuan, a decrease of 99.77% over the same period of last year Among them, the sales expense is 0, down 100% compared with 36.3599 million yuan in the same period of last year The report points out that it is due to 100% equity transfer of Kaiyuan Commercial Co., Ltd., a subsidiary, in the same period of the first half of the year, and the impact of divestiture of retail business.